In a nutshell This study is investigating how well nivolumab (Opdivo) works with DA-REPOCH chemotherapy for treating aggressive B-cell non-Hodgkin's lymphoma (NHL). The primary outcome to be measured is 2-year survival without disease progression after treatment. This study is being conducted in Columbus, OH, in the United States. The...
Read MoreIn a nutshell This phase 1/2 trial will investigate the safety and effectiveness of APL-101 in advanced non-small cell lung cancer (NSCLC). The main outcomes will be to determine the recommended phase 2 dose (RP2D) and the response rate (RR) in phase 2. This trial is recruiting at multiple locations across the US. The details...
Read More
In a nutshell This trial is examining the most beneficial dose of an experimental AE37 vaccine when used with biological therapy pembrolizumab (Keytruda). The main outcomes to be measured are the maximum safest dose of AE37 and objective response rate. This study is recruiting in Illinois and West Virginia, US. The details Triple-negative...
Read MoreIn a nutshell This phase 2 trial will investigate the effect of gemcitabine (Gemzar) and nivolumab (Opdivo) in patients with metastatic small-cell lung cancer (SCLC). The main outcome will be the radiographic response rate (RRR). This trial is recruiting in North Carolina, US. The details Small cell lung cancer...
Read More
In a nutshell This phase 1/2 trial is examining the effectiveness of treatment with GB1275 alone or in combination with immunotherapy in patients with solid tumors such as triple-negative breast cancer. The main outcome to be measured will be dose toxicity and tumor response to the treatment. This study is being conducted in Tennessee and Texas, US. The...
Read MoreIn a nutshell This phase 1b/2 trial will investigate the safety of cabozantinib (Cabometyx) with atezolizumab (Tecentriq) in patients with advanced solid tumors. The main outcomes will be the maximum tolerated dose (MTD) and overall response rate (ORR). The details Advanced cancers have limited treatment options. Surgery may not be possible. In many...
Read MoreIn a nutshell This phase 1b/2 trial will investigate the safety of cabozantinib (Cabometyx) with or without atezolizumab (Tecentriq) in patients with advanced solid tumors. The main outcomes will be maximum tolerated dose (MTD) and overall response rate (ORR). The details Advanced cancers have limited treatment options. Surgery may...
Read More
In a nutshell This study examined if a modified version of doxorubicin (Adriamycin) in ABVD chemotherapy was safe and effective in patients with Hodgkin’s lymphoma who had heart disease. This study found that this regimen was safer and just as effective as conventional ABVD. Some background Hodgkin’s lymphoma (HL) is a cancer of white...
Read More
In a nutshell This trial is investigating the effectiveness and side effects of nivolumab (Opdivo) with a dendritic cell vaccine for patients with multiple myeloma (MM). The main outcome of this study would be to see the number of patients that develop an allergic reaction to the treatment. This study is recruiting in Boston, MA, United...
Read MoreIn a nutshell This phase 1b/2 trial will investigate the safety of RMC-4630 and cobimetinib (Cotellic) in relapsed or unresponsive solid tumors. The main outcomes will be the number of side effects and the overall response rate. This trial is recruiting in a number of US states. The details Relapsed/refractory (R/R) cancer is a term for...
Read More
In a nutshell This trial is investigating the effectiveness of adding chemotherapy drug venetoclax to a standard chemotherapy treatment for patients with acute myelogenous leukemia (AML). The main outcome for this study would be the maximum amount of the drug that gives the most benefits to patients and the effectiveness of the drug. This study...
Read More
In a nutshell This phase 1/2 trial is examining the effectiveness of liposomal irinotecan (LI; Onivyde) and rucaparib (Rubraca) in treating patients with advanced colorectal cancer. The main outcome to be measured will be the toxicity and tumor response to the treatment. This trial is being conducted in Arizona, Georgia, Minnesota, and Utah, US. The...
Read More
